T1	intervention 0 28	Impact + resistance training
T2	eligibility 74 120	prematurely menopausal breast cancer survivors
T3	total-participants 818 820	71
T4	age 836 846	46.5 years
T5	control 1042 1058	exercise placebo
T14	outcome 1837 1853	increases in %BF
T15	outcome 1948 1967	improvements in %BF
T20	outcome 1740 1751	spine-POWIR
T21	iv-bin-percent 1862 1868	0.01 %
T22	cv-bin-percent 1879 1884	1.3 %
T6	iv-cont-mean 1674 1679	0.004
T7	iv-cont-sd 1682 1692	0.093 g/cm
T16	cv-cont-mean 1706 1712	-0.010
T17	cv-cont-sd 1715 1725	0.089 g/cm
T18	iv-cont-mean 1753 1759	-0.003
T23	iv-cont-sd 1762 1772	0.114 g/cm
T19	cv-cont-mean 1786 1792	-0.020
T24	cv-cont-sd 1795 1805	0.110 g/cm
T25	outcome 1586 1600	BMD at the hip
T26	outcome 1612 1633	BMD loss at the spine
T13	outcome 1654 1672	femoral neck-POWIR
T9	outcome 1404 1429	group Ã— time interactions
T8	outcome-Measure 1100 1117	hip and spine BMD
T10	outcome-Measure 1155 1171	body composition
T11	outcome-Measure 1200 1217	lean and fat mass
T12	outcome-Measure 1245 1266	bone turnover markers
T27	outcome-Measure 1320 1346	urinary deoxypryrodinoline
